

Date: August 4, 2023

To,

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 543434 National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051 NSE Symbol: SUPRIYA

Dear Sir/Madam,

<u>Subject:</u> Statement of deviation or variation in the use of proceeds of the fresh issue of the Initial Public Offer of the Company

Pursuant to Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended June 30, 2023 in the prescribed format. Further, we hereby confirm that there is no deviation or variation in the utilisation of IPO proceeds from the objects stated in the prospectus dated December 21, 2021.

Kindly take the same on record and acknowledge the receipt.

Thanking you,

For Supriya Lifescience Limited

Shweta Singh Company Secretary & Compliance Officer Membership No.: A44973

Corporate office

: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.

Tel: +91 22 40332727 / 66942507

Fax: +91 22 26860011

GSTIN: 27AALCS8686A1ZX

CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory

: A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.— Khed, Dist. — Ratnagiri, Pin :415 722, Maharashtra, India. Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com



Annexure A

Statement of Deviation / Variation in utilisation of funds raise

Name of listed entity	Supriya Lifescience Limited		
Mode of Fund Raising	Public Issues (Initial Public Offer)		
Date of Raising Funds	Issue Open Date: December 16, 2021 Issue Closing Date: December 20, 2021 Date of Listing: December 28, 2021		
Amount Raised	Offer for Sale: Rs.5,000 Million Fresh Issue: Rs.2,000 Million Total: Rs.7,000 Million		
Report filed for Quarter ended	June 30, 2023		
Monitoring Agency	Applicable		
Monitoring Agency Name, if applicable	ICICI Bank Limited		
Is there a Deviation / Variation in use of funds raised	No		
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable		
If Yes, Date of shareholder Approval	Not Applicable		
Explanation for the Deviation / Variation	Not Applicable		
Comments of the Audit Committee after review	No Comments		
Comments of the auditors, if any	No		



Corporate Office: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400 063. Maharashtra, India.

Tel: +91 22 40332727 / 66942507 | Fax: +91 22 26860011 | GSTIN: 27AALCS8686A1ZX

CIN: L51900MH2008PLC180452 | Email: supriya@supriyalifescience.com | | Website: www.supriyalifescience.com

Factory : A 5/2, Lote Parshuram Industrial Area, M.I.D.C, Tal. - Khed, Dist.-Ratnagiri, 415 722, Maharashtra, India.

Tel.: +91 2356 672300 / 200 Fax: +91 2356 272178 E-Mail: factory@supriyalifescience.com



Objects for which funds have been raised and where there has been a deviation, in the following table							
Original Object	Modified Object, if any	Original Allocation (in million)	Modified allocation, if any	Funds Utilised (in million)	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any	
Funding Capital Expenditures	Not Applicable	923.00	Not Applicable	299.07	Not Applicable	No Deviation	
Repayment and/or pre- payment, in full or part	Not Applicable	600.00	Not Applicable	600	Not Applicable	No Deviation	
General Corporate Purpose	Not Applicable	359.52	379.99*	350.95	Not Applicable	No Deviation	

^{*}On finalization of offer expenses, the amount proposed to be utilized for General Corporate Purposes is revised to INR. 379.99 million as compared to original amount of INR. 359.52 million.

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc

K. MUMBAI M MUM

Name of the Signatory: Krishna Raghunathan Designation: Chief Financial Officer

Corporate Office: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400 063. Maharashtra, India.

Tel: +91 22 40332727 / 66942507 | Fax: +91 22 26860011 | GSTIN: 27AALCS8686A1ZX

CIN: L51900MH2008PLC180452 | Email: supriya@supriyalifescience.com | | Website: www.supriyalifescience.com

Factory : A 5/2, Lote Parshuram Industrial Area, M.I.D.C, Tal. - Khed, Dist.-Ratnagiri, 415 722, Maharashtra, India.

Tel.: +91 2356 672300 / 200 Fax: +91 2356 272178 E-Mail: <u>factory@supriyalifescience.com</u>